Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9687557
SERIAL NO

15232844

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE;INSTITUT CURIE;ONXEO

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dutreix, Marie L'Hay-les-Roses, FR 17 56
Quanz, Maria Paris, FR 5 20
Sun, Jian-Sheng Saint Maur des Fosses, FR 12 48

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 27, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00